D&A at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s D&A?
- Immix Biopharma, Inc. (IMMX) reported D&A of $91.58K in Q1 2026.
- How has Immix Biopharma, Inc.'s D&A changed year-over-year?
- Immix Biopharma, Inc.'s D&A increased by 140.0% year-over-year, from $38.15K to $91.58K.
- What is the long-term trend for Immix Biopharma, Inc.'s D&A?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s D&A has grown at a 215.9% compound annual growth rate (CAGR), from $2.47K to $245.75K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.